Research presented this month at the ESC Congress in Paris suggests that getting a yearly influenza shot could greatly cut hypertensive patients’ risk of dying during flu season.

Biomedical tech company Biobeat has received 510K clearance for its noninvasive, cuffless BP-monitoring systems.

Months after the latest losartan recall and more than a year after drug companies first started pulling bulk lots of angiotensin II receptor blockers (ARB) from pharmacy shelves, the FDA has issued a statement updating the American public on the scope of the situation.

Anxiety about rejection and abandonment in close relationships could be a risk factor for cardiovascular disease, a study out of Concordia University has found.

An editorial published in the latest issue of The Lancet suggests physicians might make quicker progress toward reducing global levels of uncontrolled hypertension if they reframe the condition as part of a patient’s whole health profile, rather than as an isolated disease.

Rates of hypertension have been climbing in the U.S. in recent years, according to an analysis by Blue Cross Blue Shield, and they’re growing fastest among millennials and adults in their mid-thirties and forties.

A multi-country study in Asia has revealed patients with both type 2 diabetes and heart failure face higher odds of structural CV abnormalities, a poorer quality of life and an increased risk of death.

An August 19 science advisory from the AHA states that a 4-gram dose of prescription omega-3 fatty acid medication can greatly reduce people’s triglyceride levels, but patients likely won’t see the same results if they turn to popular—yet unproven—fish oil therapies.